Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Trevi Therapeutics Prices $150 Million Public Offering
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$2.20B |
$21.47
+0.09%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.19B |
$5.89
+1.29%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$2.13B |
$37.31
+5.57%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS is an oral small-molecule therapeutic, and Aurinia's AUR200 program reflects a focus on oral small-molecule therapeutics in its pipeline.
|
$2.12B |
$16.06
+1.45%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.11B |
$16.48
+2.42%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$2.11B |
$24.20
+1.66%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.10B |
$21.66
+0.09%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.09B |
$9.82
+10.89%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$2.08B |
$27.86
+2.41%
|
|
NEOG
Neogen Corporation
MDS pathogen detection platform and Petrifilm-based environmental testing are diagnostic equipment offerings.
|
$2.07B |
$9.51
+2.87%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Lead assets PYRUKYND (mitapivat) and tebapivat are oral small-molecule PK activators targeting red blood cell metabolism in rare hematologic diseases, representing Agios's core product strategy.
|
$2.05B |
$35.13
+0.60%
|
|
EYE
National Vision Holdings, Inc.
Provides eye care services including eye exams across its store network.
|
$2.04B |
$25.68
+3.26%
|
|
SEM
Select Medical Holdings Corporation
Direct hospital services provider; SEM's core revenue comes from Hospital Services including inpatient rehabilitation and CIRH.
|
$2.03B |
$16.40
+0.06%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.02B |
$18.35
+3.50%
|
|
GRAL
GRAIL, Inc.
Galleri is a liquid biopsy-based multi-cancer early detection test using cfDNA methylation, the core product.
|
$2.02B |
$51.66
+4.43%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$2.00B |
$9.49
-0.26%
|
|
MD
Pediatrix Medical Group, Inc.
Provides hospital-based neonatal and maternal-fetal care services (NICU care and maternal-fetal medicine) delivered in hospital settings.
|
$1.98B |
$23.06
+3.83%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.97B |
$3.79
+5.14%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.95B |
$15.21
+4.64%
|
|
ESTA
Establishment Labs Holdings Inc.
Motiva implants, tissue expanders, and related breast prosthetic devices are the core product line, i.e., prosthetics & implants.
|
$1.95B |
$67.19
+4.15%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.94B |
$43.56
-3.71%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$1.93B |
$29.27
+1.42%
|
|
WGS
GeneDx Holdings Corp.
Laboratory testing services and advisory components of genetic diagnostics.
|
$1.91B |
$66.00
+0.89%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.90B |
$35.57
+1.28%
|
|
SKWD
Skyward Specialty Insurance Group, Inc.
Accident & Health activities include health insurance lines (group stop-loss and related A&H offerings).
|
$1.90B |
$46.80
+1.16%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.89B |
$39.91
+0.92%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.87B |
$67.48
+0.87%
|
|
TNET
TriNet Group, Inc.
Health Insurance as TriNet provides employee group health benefits to client workforces.
|
$1.86B |
$38.76
-0.24%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.86B |
$28.52
-0.90%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Generics business forms a major revenue stream, with numerous generic products and the Prucalopride CGT-exclusive launch.
|
$1.82B |
$80.97
+3.71%
|
Showing page 11 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
